Cart
sales@molnova.com
Opicinumab
CAS No. 1422268-07-2
Opicinumab( —— )
Catalog No. M36887 CAS No. 1422268-07-2
Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 511 | In Stock |
|
| 10MG | 825 | In Stock |
|
| 25MG | 1216 | In Stock |
|
| 50MG | 1609 | In Stock |
|
| 100MG | 2167 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOpicinumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionOpicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.
-
DescriptionOpicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1422268-07-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cadavid D, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16(3):189-199.?
molnova catalog
related products
-
Broxiquinoline
Broxyquinoline is an antiprotozoal agent and able to release oxygen free radicals from the water in mucous membranes.
-
Ursodeoxycholic Acid...
Ursodeoxycholic Acid-d4 (Ursodeoxycholic acid-2,2,4,4-d4) is the deuterium substitute of Ursodeoxycholic acid, and is an internal standard for the quantitative determination of Ursodeoxycholic Acid (UDCA) levels by LC/MS or GC/MS.
-
EB-47
EB-47 mimics the substrate NAD+ and extends from the nicotinamide to the adenosine subsite.EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC50 value of 45 nM.
